With operations beginning in the fourth quarter, Amgen said Friday that it is opening a new site in Hyderabad, India, with 3,000 employees.
Dubbed a tech and innovation facility to “accelerate digital capabilities” to advance Amgen’s pipeline, the company said that the new site will strengthen its work around AI and data science, among other areas.
According to Amgen, Hyderabad was chosen because of its talent in medicine, life and data sciences and AI. Amgen selected Som Chattopadhyay as national executive to lead the company, known as Amgen India.
Hyderabad is the capital and largest city of the Indian state of Telangana.
“Amgen has been a leader in biotechnology for over 40 years and establishing this new site in India, a country known for its world-class technology and life sciences talent, marks a significant step forward in our journey to deliver on our mission to serve patients,” Amgen executive VP and chief technology officer David Reese wrote in a statement.
In addition to Amgen, in March, Bristol Myers Squibb CEO Chris Boerner said that by 2025, Hyderabad will have the company’s largest site outside the US. It currently has a $100 million life science hub in Hyderabad, which has 900 staffers with a focus on IT and drug development. The site will eventually employ more than 1,500 people, with an expanded focus on global business operations. Bristol Myers also has an R&D site in Bangalore.